From it’s beginning back in 1998, Seattle Genetics has been growing bigger and producing better Bio-Technology products for the fight against cancer. Located in the Seattle suburb of Bothell, Washington; Seattle Genetics has grown into the leader of this ever changing industry. With more than 800 employees, the company is one of the area’s largest job producer. The company specializes and focuses on developing and commercializing Antibody Based Therapies. These therapies treat cancer very effectively and the company’s (ADCs) Antibody Drug Conjugates, have targeting abilities to deliver a direct cell killing agent straight into cancer cells, which spares non-targeted cells. Seattle Genetics uses this style of therapy very efficiently and the company’s most popular medicine (ADCETRIS), is now available in up to 65 countries worldwide. Being such a leading figure, Seattle Genetics has many more medicines in it’s pipeline which will be used in future endeavors.
Any great company more than likely has great leadership and Seattle Genetics is no exception. Dr. Clay Siegall is the captain of this ship as well as President and CEO. Dr. Siegall knows what it takes to run a successful practice and he has an immense resume to back it up. Before Seattle Genetics’ genesis, Dr. Siegall has worked with many high profile names in the medical industry such as Bristol-Myers Squibb, National Institute of Health, and the National Cancer Society. The good doctor is a former Graduate of the University of Maryland with a (BS) in Zoology and a Graduate from George Washington University with a Ph.D in Genetics.
Dr. Clay Siegall has a strong passion for helping others and his advancements in the fight against cancer is setting the bar very high for his contemporaries. He’s a scientist/doctor and author with more than 70 publications to date. Can’t forget to mention that he’s won many awards in the field and Siegall currently holds 15 patents at present time. Clay Siegall and Seattle Genetics is revolutionizing the fight against cancer one patient at a time.
More on Clay Siegall: